On April 28, 2025, Relmada Therapeutics reported initial positive data from its Phase 2 study of NDV-01 for treating non-muscle invasive bladder cancer, showing 90% of patients achieved disease-free status. The study included 20 patients, with an overall response rate of 85% after three months, indicating strong clinical activity and supporting further development.